Genedrive (GDR) Investor update summary

Company overview and strategy

• Focused on rapid pharmacogenetic testing to improve patient outcomes in acute care, with two main products: MT-RNR1 (prevents antibiotic-induced hearing loss in newborns) and CYP2C19 (guides antiplatelet therapy in stroke patients).

• Products are CE-IVD certified, used in NHS and internationally, and supported by NICE recommendations and strong health economic evidence.

• Business model centers on a recurring consumables approach, with a capital-light structure and scalable manufacturing.

• Early commercial traction in the UK, Ireland, Saudi Arabia, and the Netherlands, with expanding distributor networks.

• Strategic focus remains on these two products, with future potential for broader pharmacogenetic applications and laboratory-based testing collaborations.

Market opportunity and adoption

• Estimated total global market opportunity is approximately £480 million, with £126 million in the UK and £190 million in CE-IVD recognized markets.

• UK market validation and adoption are key to supporting international expansion, especially in Europe and the Middle East.

• NHS Scotland has implemented MT-RNR1 nationally, while NHS England adoption is tied to NICE guidance and national reimbursement expected in July 2027.

• International traction is growing, with recent implementations in the Netherlands and Saudi Arabia, and ongoing commercial activities in Spain and the UAE.

• U.S. market entry is a longer-term goal, with FDA submission for CYP2C19 underway.

Financial performance and outlook

• Revenue has grown from £0.06 million in FY 2023 to £0.5 million in FY 2024, with projections of £1 million in FY 2025 and £1.4 million in FY 2026.

• Operating cash burn is approximately £0.35 million per month, with £3 million cash reported at June 2026.

• Targeting positive EBITDA in H2 FY 2027, driven by recurring revenue from consumables and disciplined cost management.

• Key revenue drivers include NHS England national tender, routine adoption in NHS trusts, international distributor expansion, and the Thermo Fisher laboratory collaboration.

• Average unit price per test is £110 for MT-RNR1 and £120 for CYP2C19.